Lhasa Limited shared knowledge shared progress
Publications
  • Publisher:
    Elsevier
  • Publication Date:
    Apr 2012
  • Reference:
    Regulatory Toxicology and Pharmacology, 2012, 62(3), pp449-455
  • DOI:
    10.1016/j.yrtph.2012.01.007
  • PMID:
  • Publication Type:
    Paper
  • Related Products:
  • Scientific Area:
  • Endpoint:
  • Industry Type:
  • Related event:

In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey

Dobo KL; Fred C; Glowienke S; Greene N; Harvey JS; Hasselgren C; Jolly R; Kenyon MO; Munzner JB; Muster W; Neft R; Reddy MV; Weiner S; White A;

With the increasing emphasis on identification and low level control of potentially genotoxic impurities (GTIs), there has been increased use of structure-based assessments including application of computerized models. To date many publications have focused on the ability of computational models, either individually or in combination, to accurately predict the mutagenic effects of a chemical in the Ames assay. Typically, these investigations take large numbers of compounds and use in silico tools to predict their activity with no human interpretation being made. However, this does not reflect how these assessments are conducted in practice across the pharmaceutical industry. Current guidelines indicate that a structural assessment is sufficient to conclude that an impurity is non-mutagenic.

Visit site

© 2019 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.